0001193125-25-209084 Sample Contracts
MAPLIGHT THERAPEUTICS, INC.Confirmatory Offer Letter • September 19th, 2025 • MapLight Therapeutics, Inc. • Pharmaceutical preparations
You are currently employed by MapLight Therapeutics, Inc. (the “Company” or “MapLight”) as Chief Medical Officer. As discussed, this confirmatory offer letter (this “Agreement”) confirms the existing terms and conditions of your employment in that role and is intended to replace and supersede any previously executed agreement covering the subject matter herein, including but not limited to your Offer Letter dated December 17, 2020 (the “Prior Agreement”). This Agreement will be contingent upon approval of the MapLight Therapeutics, Inc. Severance and Change in Control Plan (the “Severance Plan”) by the Company’s Board of Directors and execution of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which the common stock is priced for the initial public offering. This Agreement will be effective upon the IPO Date (as defined in the Severance Plan) (the “Effective Date”).
MAPLIGHT THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 19th, 2025 • MapLight Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 18, 2025, by and among MapLight Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the persons and entities identified on Schedule A attached hereto (the “Investors”). The Company and each of the Investors are a “party” and collectively are the “parties.”
MAPLIGHT THERAPEUTICS, INC. INDEMNITY AGREEMENTIndemnification Agreement • September 19th, 2025 • MapLight Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20___, is made by and between MAPLIGHT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
ADVISOR AGREEMENTAdvisor Agreement • September 19th, 2025 • MapLight Therapeutics, Inc. • Pharmaceutical preparations
This Advisor Agreement (the “Agreement”) is entered between Alvarado Therapeutics, Inc. (“Company”) and Robert Malenka (“Advisor”) as of February 25th, 2019 (“Effective Date”). Company and Advisor agree as follows:
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 19th, 2025 • MapLight Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT is entered into as of June 18, 2020, by and between MAPLIGHT THERAPEUTICS, INC., a Delaware corporation (“Purchaser”) and NEUROSOLIS, INC., a Wisconsin corporation (“Seller”). Purchaser and Seller are sometimes referred to individually as a “party” and collectively as the “parties”. Certain capitalized terms used in this Agreement and not defined in this Agreement are defined in Exhibit A attached to this Agreement.